Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
Last trade$84.36
Day change-$1.995 (-2.31%)
Day range$84.19 – $90.13
Volume196,005
Market cap$5.17B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.17B
Price / earnings
32.31×
Price / book
2.97×
Price / sales
3.21×
EV / sales
3.36×
EV / EBITDA
15.79×
Profitability
Earnings per share
$2.67
Return on assets
5.47%
Return on equity
9.18%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.42×
Current ratio
4.52×
Quick ratio
3.05×
Cash ratio
1.9×
Cash flow
Price / cash flow
18.9×
Price / free cash flow
25.41×
Free cash flow
$203.59M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MMSI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$416.24M
$418.84M
$381.88M
$393.94M
$384.16M
$382.46M
$355.35M
$355.16M
Cost of revenue
$215.61M
$203.68M
$197.08M
$198.58M
$197.75M
$197.98M
$183.33M
$182.18M
Gross profit
$200.63M
$215.17M
$184.8M
$195.35M
$186.41M
$184.49M
$172.02M
$172.98M
Selling, general and administrative
$119.51M
$129.23M
$118.21M
$114.83M
$119.8M
$113.1M
$107.49M
$111.07M
Research and development
$22.39M
$25.39M
$22.61M
$26.54M
$23.97M
$24.37M
$22.48M
$25.19M
Total operating expenses
$141.87M
$154.76M
$140.64M
$141.16M
$143.8M
$137.61M
$130.99M
$136.42M
Operating income
$58.76M
$60.4M
$44.16M
$54.2M
$42.61M
$46.88M
$41.03M
$36.56M
Interest expense
-$7.33M
-$12.12M
-$6.53M
-$6.36M
-$6.75M
-$6.78M
-$6.57M
-$7.99M
Income before taxes
$55.79M
$51.31M
$53.55M
$51.06M
$38.54M
$43.38M
$37.96M
$33.15M
Income taxes
$13.47M
$12.51M
$12.55M
$13.05M
$10.79M
$10.8M
$7.81M
$5.2M
Net income
$42.31M
$38.8M
$41M
$38.01M
$27.76M
$32.58M
$30.15M
$27.95M
Net income attributable to common shareholders
$42.31M
$38.8M
$41M
$38.01M
$27.76M
$32.58M
$30.15M
$27.95M
EBITDA
$90.61M
$91.45M
$74.65M
$85.73M
$73.93M
$77.9M
$70.33M
$65.18M
Basic earnings per share
$0.71
$0.65
$0.69
$0.64
$0.47
$0.55
$0.51
$0.48
Diluted earnings per share
$0.70
$0.65
$0.68
$0.63
$0.46
$0.54
$0.49
$0.46
Recent news
Company coverage with links to the original publishers.
Merit Medical Systems announced positive real-world clinical data from its WRAPSODY Cell-Impermeable Endoprosthesis, demonstrating 92.7% six-month target lesion primary patency and 76.7% access circuit primary patency, both exceeding WAVE trial results. The device received FDA approval in December 2024 and is now being commercialized in the U.S., with ongoing registry studies expected to generate comprehensive clinical evidence supporting wider physician adoption in the growing dialysis access market.
Hims & Hers (HIMS) reported Q3 2026 EPS of 3 cents, missing estimates by 57.1%, though revenues grew 48.7% year-over-year to $890.4 million. The company faced margin compression due to lower-margin weight loss products and a sequential subscriber decline of 100,000. HIMS lowered its full-year adjusted EBITDA guidance to $257-$277 million but raised international revenue outlook to at least $650 million.
Rigetti Computing (RGTI) reported Q2 2026 adjusted loss per share of 6 cents with revenues declining 27.5% to $1.41 million, missing consensus estimates by 57.6%. Despite gross margin expansion to 60.7%, operating losses widened to $33.19 million due to increased R&D spending. The company targets $20 million in 2026 revenues and plans to develop a 300+ qubit quantum system by mid-2028.
Veeva Systems (VEEV) is well-positioned for growth driven by its diversified product portfolio, strong Q2 fiscal 2027 results, and accelerating Vault CRM adoption with over 180 customers live and 12 of top 20 biopharma commitments. However, market saturation in the life sciences CRM sector poses a headwind to future growth rates. The company raised its fiscal 2027 outlook and expects 35% growth over the next five years.
Merit Medical Systems (MMSI) reported 8% Q3 2026 revenue growth to $416 million, driven by strong foundational and therapeutic product performance, strategic acquisitions like Solo Pace, and innovation in oncology and endoscopy. However, the company faces headwinds from China market pricing pressures, competitive challenges in the WRAPSODY renal therapies platform, and $16 million in incremental tariff costs impacting 2026 profitability.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.